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Abstract
In prokaryotes, vitamin K2 (menaquinone) transfers two electrons in a process of aerobic
or anaerobic respiration. Respiration occurs in the cell membrane of prokaryotic cells.
Electron donors transfer two electrons to menaquinone (MK). Menaquinone in turn
transfers these electrons to an electron acceptor. Menaquinones are vital for the electron
transport chain. In the spectrum of Gram‐positive bacteria and Mycobacterium  spp.,
vitamin K2 serves as the only quinone molecule in their electron shuffling systems.
Hence, the bacterial enzymes associated with biosynthesis of the menaquinone(s) serve
as potential  target molecules for the development of new antibacterial  drugs. This
chapter summarizes the effects of vitamin K2 in bacteria and describes in more detail
the  aspects  of  menaquinone  in  bacterial  electron  transport  in  general,  while  also
featuring the discoveries of menaquinone biosynthesis inhibitors.
Keywords: vitamin K1, vitamin K2, menaquinone, menaquinone biosynthesis, electron
transport systems, ATP biosynthesis, Gram‐positive bacteria, Mycobacterium tuberculo‐
sis, antibacterial agents
1. Introduction
Vitamin K is a lipid‐soluble vitamin that facilitates the process of blood clot formation. Henrick
Dam and Edward Doisy were co‐awarded the Nobel Prize in 1943 for the discovery of vitamin
Ks and the discovery of their structure. Naturally existing forms of vitamin K, vitamin K1 (i.e.,
phylloquinone), and vitamin K2 (i.e., menaquinone) can be found in the human liver (some 10%
of phylloquinone of the total vitamin K contents), as well as in other tissues in rather low amounts;
vitamin K1 accumulates in the liver, while vitamin K2 is effectively distributed to other body
organs [1]. Phylloquinone stems from the dietary intake, while menaquinones are synthesized
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by bacteria of the intestine. However, no direct evidence can be established for the biological
effects of menaquinones in humans; however, it is surmised that menaquinones mainly are
utilized in the synthesis of blood‐clotting factors upon the depletion of phylloquinone [2].
Additionally, menaquinones have proven to be more efficient than phylloquinone as a bioactive
molecule in processes such as osteroclast differentiation, lowering of blood cholesterol levels,
as well as the slowing down of atherosclerotic progression.
The menaquinones have proven to be important in several biological reactions, for example
electron transport, active transport, oxidative phosphorylation, as well as endospore formation
in bacteria. Furthermore, variations in the inherent molecular structures of the menaquinones
and their skewed distributions among bacterial strains are considered as an important marker
in bacterial taxonomy [3]. The biosynthesis of menaquinone has been subject to considerable
attention in the quest for drug targets displaying multidrug resistance toward Gram‐positive
pathogenic microorganisms, including Mycobacterium tuberculosis.
2. Vitamin K: general molecular structures
There are two naturally occurring forms of vitamin K. Plants and some cyanobacteria synthe‐
size phylloquinone, which is also known as vitamin K1. Bacteria synthesize a range of vitamin
K, but not vitamin K1, using the different lipophilic side chains derived from isoprene (5‐
carbon) units. Bacterial vitamin K(s) are designated menaquinone‐n (MK‐n), where “n” stands
for the number of isoprenoid (5‐carbon) units. Vitamin K1 and K2 share the common molecular
structure, belonging to the 2‐methyl‐1,4‐naphthoquinone system, and they appear to be differ
structurally in their number of isoprene units within their side chain, as well as their degree
of unsaturation [4] (Figure 1). Menaquinones, displaying side chains containing up to 15
isoprene units have been identified. For instance, MK‐8 is predominantly seen in E. coli, while
M. tuberculosis mainly utilizes MK‐9 as the preferred electron carrier. The menaquinones, which
possess from 2 to 13 isoprene units, have been detected in both human and animal tissues. A
plethora of synthetic vitamin K(s) are now commercially available, and biochemically fabri‐
cated vitamin K(s), in the form of vitamin K3, K4, and K5, are applied in several areas, which
include pet food industry (e.g., VK3), as well as human supplements (e.g., VK5).
Figure 1. Structures of vitamin K1 and K2 and synthetic vitamin Ks (vitamin K3, K4, and K5).
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3. Vitamin K in humans
The role of vitamin K as a cofactor in blood coagulation stems from the post‐translational
modification of a number of plasma proteins such as factors II, VII, IX, X, proteins C, S, Gla
(γ‐carboxyglutamic acid) proteins has been well‐documented. In addition to the essential
role of vitamin K in the blood‐clotting cascade, the potential role in the increase of bone mass
[5, 6], antioxidant mechanisms [7], the biosynthesis of cholesterol and steroid hormones [8],
and anticancer effects have been reported [9, 10].
Vitamin K is taken up by organs such as the liver and bones, but abundantly distributed in
other organs such as the brain, the kidneys, and gonadal tissues [11]. However, the exact role
of vitamin K in the present tissues is not well described. The distribution of vitamin K moieties
is varying, which depends on the molecular structure of the side chain. As for humans,
vitamin K1 is distributed to all tissues and organs, with relatively large amounts to the liver,
the heart, and the pancreas (some 10.6, 9.3, 28.4 pmol/g wet tissue weight, respectively).
However, low levels (<2 pmol/g) were measured in the brain, kidney, and lung tissue speci‐
mens. Menaquinone‐4 (MK‐4) also seems to be distributed to a plethora of other tissues, that
is, its levels exceed the levels of vitamin K1 detected in the brain and kidneys (2.8 ng/g), which
equals to that found in the pancreas. However, some organs, such as the liver, heart, and lung
remain low in terms of MK‐4 contents. The less known MK‐6 ∼ 11 menaquinone species are
also found in the liver, while only small amounts of MK‐6 ∼ 9 are detected in organs such as
the heart and pancreas. Finally, the total amount of vitamin K reported in human plasma was
in the range of 0.47 ∼ 1.19 nmol/L [1, 12].
Vitamin K can be absorbed well from diet; however, total vitamin K levels are depend greatly
on the gut or digestive health. The intestinal bacteria (i.e., microbiota) influence human
nutrition and metabolism in diverse ways. The gut microbiota produces menaquinone; thus,
it is considered that vitamin K deficiency is quite rare for healthy humans. In addition, the
vitamin K1 is absolutely abundant in leafy and salad vegetables, and herbs. It is easy to
understand that newborn babies are born with a vitamin K deficiency, giving newborns a
vitamin K injection upon birth or oral vitamin K drops is established to prevent bleeding or a
hemorrhagic disease development. In general, vitamin K deficiency results from extremely
inadequate intake of fat (malabsorption) or use of coumarin anticoagulants.
4. The role of vitamin K2 in electron transport system
Function of ubiquinone (Q) (coenzyme Q10) as a component of the mitochondrial respiratory
chain in human is well established (“the chemiosmotic theory,” Mitchell, 1978). In prokaryotes,
especially in Gram‐positive bacteria, vitamin K2 (menaquinone) will transfer two electrons in
a process of aerobic or anaerobic respiration. Respiration occurs in the cell membrane of
prokaryotic cells. Electron donors transfer two electrons to menaquinone. Menaquinone in
turn transfer these electrons to an electron acceptor. Schematic electron flow mediated by
menaquinone in M. tuberculosis is illustrated in Figure 2A. The exact organization of enzymes
Vitamin K2 Biosynthesis: Drug Targets for New Antibacterials
http://dx.doi.org/10.5772/65487
283
in respiratory chains will vary among different bacteria. Nicotinamide adenine dinucleotide
phosphate (NADH) is the most important electron donor in eukaryotes (Figure 2B); however,
bacteria can use a number of different electron donors, dehydrogenases, oxidases and
reductases, and electron acceptors. Electrons are transported along the membrane through
menaquinone and a series of protein carriers.
Figure 2. Schematic electron flow systems. (A) Electron transport systems of Gram‐positive bacterial and Mycobacteri‐
um spp. (B) Mitochondrial electron transport chain.
Protons are translocated across the cell membrane (from the cytoplasm to the periplasmic
space) concomitantly. Synthesis of Adenosine triphosphate (ATP) from ADP and phosphate
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is coupled with protons move through these complexes (Figure 2). Therefore, CoQ10 and
menaquinone occupy a central and essential role in Adenosine triphosphate (ATP) synthesis
[13, 14]. From the taxonomic studies, it is evident that the majority of Gram‐positive bacteria
including Mycobacterium spp. utilize only menaquinone in their electron transport systems
[15], and menaquinone biosynthesis is essential for survival of Gram‐positive bacteria [16, 17].
Several in vitro studies indicated that exogenous menaquinone did not rescue the bacteria
treated with selective menaquinone biosynthesis inhibitors [18]. Menaquinone biosynthesis
has been extensively studied in E. coli. A plethora of Gram‐negative organisms use CoQ in
their electron transport systems when aerobic conditions prevail, but menaquinone under
anaerobic conditions. However, the reaction chain facilitating electron transport humans does
not use menaquinone. Unquestionably, the chain of reactions funneling the transport of
electrons serves as a central component in the synthesis of Adenosine triphosphate (ATP) and
the subsequent multiplication of bacteria (Figure 2). Hence, inhibitors of the biosynthesis of
menaquinone or inhibitors specifically targeting the enzymes linked to electron transport
systems display the potential for the development of novel and selective drugs against
multidrug‐resistant (MDR) Gram‐positive bacteria. Although the functions of vitamin K1 in
humans and vitamin K2 in bacteria are entirely different, drug discovery targeting vitamin K2
or its biosynthesis requires careful consideration of vitamin K distribution in tissue and
selectivity against the target protein because essential vitamin K‐dependent protein(s) may be
interfered by vitamin K biosynthesis inhibitors. Nonetheless, many evidences support that
menaquinone biosynthesis inhibitors can be developed into selective antibacterial agents for
infections caused by Gram‐positive bacteria and Mycobacterium spp.
5. Biosynthesis of menaquinone
Menaquinones play an important role in electron transport, and oxidative phosphorylation.
In addition, they are responsible for active transport, and endospore formation in some Bacillus
species [19]. The biosynthetic steps leading to menaquinone have been studied in E. coli (vide
supra) [19, 20]. The synthesis of menaquinone is accomplished by MenA‐MenG as illustrated
in Figure 3. These enzymes are encoded by two clusters of genes. The men gene cluster
consists of the MenB, C, D, E, and F and a separate cluster containing MenA and MenG [21, 22].
The biosynthesis of menaquinone is initiated from chorismate and proceeds through a series
of menaquinone‐specific reactions. MenF is isomerizing to chorismate in order to form
isochorismate. MenD (a thiamine diphosphate‐dependent enzyme) catalyzes a Stetter‐like
conjugate addition (a 1,4‐addition of an carbonyl molecule to α β‐unsaturated compound) of
α‐ketoglutarate with isochorismate, forming 2‐succinyl‐5‐enolpyruvyl‐6‐hydroxy‐3‐cyclohex‐
adiene‐1‐carboxylate. Its pyruvate moiety is eliminated by MenH to yield 2‐succinyl‐6‐
hydroxy‐2,4‐cyclohexadiene‐1‐carboxylate. MenC catalyzes aromatization of 2‐succinyl‐6‐
hydroxy‐2,4‐cyclohexadiene‐1‐carboxylate, forming o‐succinylbenzoate. MenE is an o‐
succinylbenzoate‐CoA ligase, which converts o‐succinylbenzoate to o‐succinylbenzoate‐CoA.
Thereafter, MenB catalyzes a formal Dieckmann type of condensation of o‐succinylbenzoate‐
CoA to yield 1,4‐dihydroxy‐2‐naphthoyl‐CoA, which, in turn, is being hydrolyzed to 1,4‐
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dihydroxy‐2‐naphthoate (DHNA) thioeter‐splitting enzyme encoded by yfbB. In contrast, the
prenyl diphosphate with appropriate size (i.e., n = 7 in E. coli) is being biosynthesized by the
iterative reaction of allyl diphosphate in the presence of isopentenyl diphosphate. Then,
DHNA is prenylated and methylated by MenA and MenG, respectively, yielding menaqui‐
nones as the end product. The side chains of menaquinones vary in different species and even
within the same organisms. The more common of menaquinones display 7, 8, and 9 isoprene
(C‐5) units; MK‐7 serves as the major menaquinone entity in several Gram‐positive spore‐
forming bacteria. MK‐8 can be found in E. coli, while MK‐9 in common in M. tuberculosis.
However, menaquinones containing 4, 5, 6, 10, 11, 12, and 13 isoprene units have been reported
in bacteria.
Figure 3. Biosynthesis of menaquinone.
Menaquinones are the predominant isoprenoid lipoquinones of Gram‐positive bacteria,
whereas Gram‐negative bacteria and enterobacteria use menaquinone (MK), demethylmena‐
quinone (DMK), and ubiquinone (Q) in their electron transport chains (Figure 2). Recent
studies have shown that several γ‐proteobacteria appear to share the similar electron transport
system to that observed in E. coli [23–26]. Several studies indicated that the regulation of
menaquinone biosynthesis of aerobically growing bacteria is different from those of bacteria
under anaerobic respiratory conditions being controlled by FNR as the general regulator.
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Additionally, the MK/DMK ratio is not dependent on the fur locus, and substantial amounts
of naphthoquinones (MK and DMK) are retrieved only during anaerobic conditions in E. coli.
The menaquinones were detected almost no exception within the bacterial membrane. The
total amount of naphthoquinones was found to be some 0.60 ∼ 1.09 μmol/g cell. It has become
evident that several bacterial species do not have methylase (or MenG) and thus produce DMK
as their sole quinone [19]. Conversion from MK to DMK is the last step in the biosynthesis.
The activity of the DMK methylase is likely to be regulated by the presence or absence of the
electron carriers or by the supply of S‐adenosylmethionine [20]. A bioinformatic analysis of
whole‐genome sequences suggested that some microorganisms, including Helicobacter pylori
and Campylobacter jejuni, and lactobacilli do not have orthologs of the men genes, although
they synthesize menaquinone. These bacteria synthesize menaquinones in an alternative
pathway via futalosine via alternative pathway (Figure 3) [23].
6. Antibacterial drug discovery by targeting menaquinone biosynthesis
Menaquinone is the sole quinone in the electron transport chain in the majority of Gram‐
positive bacteria including Mycobacterium spp. The biosynthetic pathway leading to menaqui‐
none is absent in humans; therefore, the bacterial enzymes responsible for menaquinone
biosynthesis are potential drug targets for development of novel antibacterial agents. It is
speculated that dormant (non‐replicating) M. tuberculosis displays a less active metabolism and
also diminished energy reserves; however, Adenosine triphosphate (ATP) synthesis during
oxidative phosphorylation is active during the dormant state. Therefore, inhibition of the
menaquinone biosynthesis might exert serious effects on the maintenance of dormancy in M.
tuberculosis. This concept emphasized the reports that phenothiazines block the type II
Nicotinamide adenine dinucleotide phosphate (NADH): menaquinone oxidoreductase
(Figure 4) in the bacterial respiratory chain and also were effective in killing non‐replicating
M. tuberculosis [27]. Interestingly, it was demonstrated that inhibition of MenA (1,4‐dihydroxy‐
2‐naphthoate prenyltransferase) (Figure 3) showed significant growth inhibitory activities
against drug‐resistant Mycobacterium spp. and Gram‐positive bacteria [28]. MenA inhibitors
Figure 4. Electron flow in M. tuberculosis and type II Nicotinamide adenine dinucleotide phosphate (NADH) dehydro‐
genase inhibitors.
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effectively killed non‐replicating M. tuberculosis in vitro. Several other promising biological date
were generated on MenA as a new antibacterial drug target; (1) M. tuberculosis growth in vitro
could not be rescued by exogenous vitamin K2 supplementation, (2) all Gram‐positive bacteria
tested (e.g., Staphylococcus aureus, Enterococcus faecalis, and Clostridium difficile) were susceptible
to MenA inhibitors, whereas Gram‐negative bacteria (E. coli, Klebsiella pneumoniae, Pseudomonas
aeruginosa, and Acinetobacter baumannii) were not susceptible under aerobic conditions, and (3)
MenA inhibitors are effective in killing E. coli under anaerobic conditions [18]. To date, several
menaquinone biosynthesis enzymes have been studies for the development of novel antibac‐
terial agents.
7. Menaquinone biosynthesis inhibitors
7.1. MenA inhibitors
Among the menaquinone biosynthesis enzymes, MenA is a membrane‐associated protein that
catalyzes prenylation of demethylmenaquinone (DMK), forming 1,4‐dihydroxy‐2‐naphtoate
(DHNA). Analyses of the amino acid sequence of MenA were revealed that MenA displays
five transmembrane segments, and that there exists highly conserved aspartate (D), which
would be localized to the inner‐plasma membrane, which was being predicted by the aid of
a prediction program (Sosui) [14]. The activity is totally dependent on the presence of divalent
cations, such as Mg2+. It is therefore likely that these divalent cations produce ion pairs with
Asp residues contained within the catalytic site within MenA. A library of DMMK mimics
possessing the amino group(s) were generated and evaluated in an enzymatic assay in vitro
(IC50) against Mtb MenA. Identified MenA inhibitors were evaluated in bacterial growth
inhibitory assays (MIC). The tertiary or secondary amine‐containing benzophenone derivatives
1 and 2 are the first‐generation MenA inhibitors that exhibited bactericidal activities against
M. tuberculosis (MIC 1–1.5 μg/mL for 1) and Methicillin‐resistant Staphylococcus aureus
(MRSA) (MIC 4.0 μg/mL for 2), respectively. These molecules are inhibited growth of drug‐
resistant Mycobacterium spp. and drug‐resistant Gram‐positive bacteria (vancomycin‐resistant
S. aureus, vancomycin‐resistant E. faecalis, and linezolid‐resistant Methicillin‐resistant
Staphylococcus aureus (MRSA)) at low concentrations [29, 30]. Significantly, the MenA
Figure 5. MenA inhibitors.
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inhibitor 1 killed non‐replicating M. tuberculosis much faster than first‐line Tuberculosis (TB)
drug, rifampicin at lower concentrations. Later, the same group developed selective antimy‐
cobacterial MenA inhibitor 3. The optically pure 3 is the most active molecule in killing non‐
replicating Mtb. In vitro data with selective MenA inhibitors suggested that menaquinone
biosynthesis is important in maintaining mycobacterial viability under conditions of restricted
oxygen [18]. MenA inhibitors are likely to block the electron flow, consequently inhibiting the
bacterial growth. The other group identified 7‐methoxy‐2‐naphthol‐based MenA inhibitors
(e.g., 4) that killed M. tuberculosis and Gram‐positive bacteria with the MIC level of 3–25 μg/mL
(Figure 5) [31].
7.2. MenB inhibitors
One of at least seven enzymes in menaquinone biosynthesis, MenB (1,4‐dihydroxy‐2‐naph‐
thoyl‐CoA synthase) forms the bicyclic ring system by catalyzing the Dieckmann type
reaction of o‐succinylbenzoyl‐coenzyme A to 1,4‐dihydroxy‐2‐naphthoic acid. A high‐
resolution co‐crystal structure of E. coli MenB with a stabilized analog of o‐succinylbenzoylCoA
was successfully diffracted. The MenB X‐ray structure provides important insight into the
catalytic mechanism. Similarly, the X‐ray structure of MenB from M. tuberculosis was charac‐
terized. A high‐throughput screen (HTS) against M. tuberculosis MenB led to the discovery of
2‐amino‐4‐oxo‐4‐phenylbutanoic acid (5) that inhibits MenB at low nanomolar concentrations
[32]. Later, methyl 4‐(4‐chlorophenyl)‐4‐oxobut‐2‐enoate (6) was reported to inhibit MenB by
forming the CoA adduct, 7. The adduct 7 binds to the S. aureus MenB with a Kd value of 2 μM,
and also killed drug‐sensitive and drug‐resistant S. aureus strains at 0.35–0.75 μg/mL concen‐
trations [33]. Bacterial growth inhibitory assays of 6 against a battery of bacteria concluded
that 6 is effective only against bacteria that utilize menaquinone for respiration. In vivo efficacy
of 1 using the mouse models of Methicillin‐resistant Staphylococcus aureus (MRSA) infection
revealed that 6 increased survival in a systemic infection model and resulted in a dose‐
dependent decrease in bacterial load [34]. These in vitro and in vivo studies came to the
conclusion that MenB is a valid target for the development of new anti‐Methicillin‐resistant
Staphylococcus aureus drug and infections caused by Gram‐positive bacterial infections
(Figure 6).
Figure 6. MenB inhibitors.
7.3. MenD inhibitors
MenD (2‐succinyl‐5‐enolpyruvyl‐6‐hydroxy‐3‐cyclohexadiene‐1‐carboxylate synthase) catal‐
yzes a thiamin diphosphate‐dependent decarboxylative carboligation of α‐ketoglutarate and
isochorismate via a Stetter‐like conjugate addition. MenD is also essential for menaquinone
Vitamin K2 Biosynthesis: Drug Targets for New Antibacterials
http://dx.doi.org/10.5772/65487
289
biosynthesis in some bacteria and has been recognized as an antibacterial drug target. A
succinylphosphonate ester, 4‐(methoxyoxidophosphoryl)‐4‐oxobutanoate (8) was reported to
be a competitive inhibitor of MenD (Ki values ∼700 nM) [35]. An analog of the cofactor,
thiamine diphosphate, oxythiamine 9 was reported to exhibit MenD enzyme and S. aureus
growth inhibitory activities (Figure 7) [36].
Figure 7. MenD inhibitors.
7.4. MenE inhibitors
MenE (o‐succinylbenzoate‐CoA synthetase) is an essential adenylate‐forming enzyme that is
also a promising target for development of novel antibiotics in the menaquinone biosynthesis.
Adenosylsulfonamide, adenosylsulfamate, and adenosylsulfamide analogs 10, 11, and 12 were
developed as inhibitors of MenE enzymes based on the structure of o‐succinylbenzoate‐CoA.
The vinyl sulfonamide 10 was found to be the most potent MenE inhibitor (IC50 ∼ 5.7 μM
against M. tuberculosis MenE) [37]. The vinyl sulfonamide 10 is a competitive inhibitor of M.
tuberculosis MenE with respect to Adenosine triphosphate (ATP) (Ki = 5.4 ± 0.1 nM) (Figure 8).
Figure 8. MenE inhibitors.
8. Conclusion
Bacterial Adenosine triphosphate (ATP) synthase, F1F0‐ATPase, is a viable target for treatment
of M. tuberculosis infections. Diarylquinolone, an inhibitor of M. tuberculosis Adenosine
triphosphate (ATP) synthase exhibited a remarkable activity against Mycobacterium spp.
Electron transport systems associated with Adenosine triphosphate (ATP) synthases are
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established drug targets for antibacterial and antiprotozoal infections. For example, Nicotina‐
mide adenine dinucleotide phosphate (NADH) hydrogenase is a sustainable drug target for
the malaria parasite and is also a promising target for M. tuberculosis infections. On the other
hand, menaquinone biosynthesis has recently been received attention for the development of
novel antibacterial agents. Menaquinone is a key component of the electron transport systems
in the majority of Gram‐positive bacteria including M. tuberculosis. As summarized in Chap‐
ter 6, inhibitors of menaquinone biosynthesis have been identified and several compounds are
also effective inhibitors of bacterial growth. In development of new drugs for M. tuberculosis
infections, it is the ultimate goal to discover a Tuberculosis (TB) drug that is effective against
human latent tuberculosis infection. Among the menaquinone biosynthesis enzymes, MenA
has been extensively studies as drug target for M. tuberculosis and Gram‐positive bacteria.
Selective MenA inhibitors inhibit the growth of non‐replicating M. tuberculosis, suggesting that
menaquinone is essential in maintaining the bacterial viability during conditions of restricted
levels of oxygen. A large set of data suggest that the DosR/DosS/DosT signaling pathway is
mandatory for M. tuberculosis’ genetic response to hypoxic conditions and nitric oxide, in the
adaptation of M. tuberculosis to conditions triggering a reversible bacteriostasis. In this way,
the DosR/DosS/DosT signaling pathway may contribute to the latency seen in vivo [38]. MenA
inhibitors display the ability to block or hamper the flow of electrons without inducing a
dormancy response in M. tuberculosis. Consequently, menaquinone biosynthesis inhibitors
have the potential to kill M. tuberculosis at any states by inhibiting Adenosine triphosphate
(ATP) synthesis non‐directory.
Recently, a narrow‐spectrum antibiotic, siamycin I was reported to kill Helicobacter and
Campylobacter by inhibiting the futalosine (alternative) pathway (Figure 3). Branched fatty
acids (12‐ or 13‐methyltetradecanoic acids) also inhibit the biosynthesis of menaquinone
biosynthesis of H. pylori. Because of advances of biological assays of menaquinone
biosynthesis, new inhibitor molecules that possess drug‐like characteristics will be identified.
It is import to prove the efficacy of menaquinone biosynthesis inhibitor using an appropriate
infected animal model. To date, in vivo efficacy of a MenB inhibitor was demonstrated using
the mouse model of Methicillin‐resistant Staphylococcus aureus (MRSA) infection. A
Tuberculosis (TB) drug, SQ109, a strong inhibitor of trehalose monomycolate (TMM)
transporter, was reported to exhibit inhibitory activities of MenA and MenG enzymes from
M. tuberculosis. Discovery of a pharmacologically acceptable menaquinone biosynthesis
inhibitor, which possesses a significant antibacterial activity against replicating and non‐
replicating M. tuberculosis, has been highlighted in Tuberculosis (TB) drug development. It is
worthwhile mentioning that menaquinone biosynthesis inhibitors are also promising agents
to kill Gram‐negative bacteria growing under oxygen‐depleted or anaerobic conditions in
which menaquinone is utilized for their respiration.
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